1. Volume 80, Issue 9, Pages 978-985 (November 2011)
Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients 
Kevin E. Chan, T. Alp Ikizler, Jorge L. Gamboa, Chang Yu, Raymond M. Hakim, Nancy J. Brown 
Kidney International 
Volume 80, Issue 9, Pages (November 2011)
DOI: /ki
Copyright © 2011 International Society of Nephrology Terms and Conditions

2. Figure 1
Cardiovascular survival curves. (a) Crude and (b) adjusted survival curves in patients in whom angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy was initiated.
Kidney International  , DOI: ( /ki )
Copyright © 2011 International Society of Nephrology Terms and Conditions

3. Figure 2
Cardiovascular survival curves. (a) Crude and (b) adjusted survival curves in patients in whom treatment was initiated with an ACEI+other antihypertensive (antiHTN) medications (ACEI+Rx), an angiotensin receptor blocker (ARB)+antiHTN (ARB+Rx), or an ACEI+ARB. ACEI, angiotensin-converting enzyme inhibitor.
Kidney International  , DOI: ( /ki )
Copyright © 2011 International Society of Nephrology Terms and Conditions